Genentech, a member of the Roche Group, announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon. The investment will double the size of the existing facility and is expected to create 250 high-wage manufacturing jobs and approximately 200 construction jobs, with commercial operations expected to begin in 2031. The new facility will support the manufacturing of advanced drug delivery devices, such as pre-filled syringes and autoinjectors, and is designed for flexible high- and low-volume device filling across Roche and Genentech's portfolio. The Hillsboro investment follows the recent topping out of Genentech's new manufacturing facility in Holly Springs, North Carolina, which will support global production of metabolic medicines including next-generation obesity treatments.
Roche Holding AGRoche's subsidiary Genentech announces $750M investment in Oregon facility, expanding manufacturing capacity.
Genentech plans $750M investment in new fill-finish facility, doubling site size and creating jobs.
